CAS: 18323-44-9; (2S,4R)-N-((1S,2S)-2-Chloro-1-((2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Methylthio)Tetrahydro-2H-Pyran-2-yl)Propyl)-1-Methyl-4-Propylpyrrolidine-2-Carboxamide

该化合物是一种林丹抗生素,主要用于治疗各种细菌感染,特别是厌氧细菌和某些原生虫引起的感染;它有效防治抗格莱阳性细菌,包括一些血压球菌株和Streptococccus; clindamycin通过抑制细菌蛋白合成,从而阻止细菌的生长和繁殖; clindamycin的化学配方是C18H33ClN2O5S, 其分子重量约为406.99克/摩尔; 它通常通过口服或静脉注射进行,并可以使用各种配方,包括胶囊,热液溶液和注射形式; Clindamycin, 因其良好的组织穿透性而著名,因此特别有助于皮肤和软组织感染的治疗; 然而,它也会导致副作用,例如胃肠扰动,在稀有的情况下, 氯丝特里迪基-相关腹泻,其分子重量约为406.9克/摩尔; 由于其行动机制和活动范围,Clindimacial被经常用作静态病人的替代品.

结构式图片

MSDS等安全信息

上下游产品

lincomycin hydr°Chloride clindamycin hydr°Chloride

合成工艺路线路线简述

    盐酸林可霉素置于光气体系中,用 氯仿,N,N-二甲基甲酰胺 用作溶剂,化学反应 2.0H,反应生成克林霉素
    参考文献:一种克林霉素磷酸酯的合成方法
    标题:一种克林霉素磷酸酯的合成方法
    摘要:本发明属于化学合成技术领域,具体涉及一种克林霉素磷酸酯的合成方法.该方法经克林霉素游离碱的合成-酮化反应-磷酰化反应-后处理制得.本发明通过改变加料顺序,步骤和催化剂,使得克林霉素磷酸酯的重量收率可达80%以上.

    海关参考信息

    专利信息


    专利号:US-2015182634-A1
    优先权日:2012-12-28
    标 题:Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
    发明人:COYNE CODY P; BEAR RYAN; JONES TONI
    权利人:COYNE CODY P; BEAR RYAN; JONES TONI
    摘要:Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma/carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2024197774-A1
    优先权日:2021-04-16
    标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
    发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
    权利人:UNIV TEXAS
    摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

    专利号:US-12221452-B2
    优先权日:2017-10-04
    标题:Synthesis of cantharidin
    发明人:DAVIDSON MATTHEW GENE; EKLOV BRIAN MATTHEW; WUTS PETER; LOERTSCHER BRAD MELVIN; SCHOW STEVEN R
    权利人:VERRICA PHARMACEUTICALS INC
    摘要:The invention provides synthetic methods for the preparation of cantharidin and analogs thereof. In one aspect, the invention provides an improved Diels-Alder cycloaddition to generate a key intermediate en route to cantharidin and analogs thereof. In certain embodiments, the new Diels-Alder reaction involves reacting Compound (2) in the presence of furan, and in the absence of acid or increased pressure, in an aprotic polar solvent with slight warming, to yield Compound (1) in favorable yield and exo-endo ratio. In another aspect, the invention also provides a new Diels-Alder reaction between compounds of Formula (III) and furan to yield compounds of Formula (IV), which can then be transformed into cantharidin or analogs thereof. In yet another aspect, the invention describes a new palladium-mediated carbonylation providing another key intermediate en route to cantharidin and analogs thereof. In addition to synthetic methods, present invention also provides compounds (i.e., intermediates) useful in the synthesis of cantharidin and analogs thereof. Compounds provided herein may have biological activity, and therefore may be used in the treatment of diseases or conditions (e.g., infectious diseases and skin conditions).

    专利号:US-11311505-B2
    优先权日:2017-02-24
    标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
    发明人:MARTIN ALAIN
    权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
    摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

    专利号:US-10308663-B2
    优先权日:2015-06-16
    标题:Inhibitors of PTP4A3 for the treatment of cancer
    发明人:LAZO JOHN S; SHARLOW ELIZABETH R; MCQUEENEY KELLEY E; WIPF PETER; SALAMOUN JOSEPH M
    权利人:LAZO JOHN S; SHARLOW ELIZABETH R; MCQUEENEY KELLEY E; WIPF PETER; SALAMOUN JOSEPH M; UNIV VIRGINIA PATENT FOUNDATION; UNIV OF PITTSBURGH —OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    摘要:The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).
    天津国恩进出口贸易有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.gnchemicals.com
    电话: 0311-85902108👤
    📞天津国恩进出口贸易有限公司 ⚠️参考联系方式

    销售电话:0311-85902108
    邮箱:info@gnchemicals.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    江苏仁信化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.trustchem.com
    电话: 25-84729803👤
    📞江苏仁信化工有限公司 ⚠️参考联系方式

    销售电话:25-84729803
    邮箱:sales@trustchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海农安国际贸易有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.safechem.com.cn
    企业联系电话:+86-21-68672030👤
    📞上海农安国际贸易有限公司 ⚠️参考联系方式
    联系人:许夏春
    电话:+86-21-68672030

    传真:+86-21-50812742
    邮箱:sales@safechem.com.cn
    通信地址: 上海东方路818号众城大厦11楼a座
    邮编: 200122
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海东方路818号众城大厦11楼a座
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Oertel R, Schubert S, Mühlbauer V, Büttner B, Marx C, Kirch W. Determination of clindamycin and its metabolite clindamycin sulfoxide in diverse sewage samples. Environ Sci Pollut Res Int. 2014 Oct;21(20):11764-9. doi: 10.1007/s11356-013-2333-2. Epub 2013 Dec 6. doi: 10.1007/s15010-015-0773-y. Epub 2015 Apr 3. doi: 10.1111/jdv.13185. Review. doi: 10.1093/cid/civ462. Epub 2015 Jun 16. doi: 10.1016/j.jpba.2014.08.023. Epub 2014 Oct 2. doi: 10.1002/jssc.201400166. Epub 2014 Aug 20. doi: 10.1684/ejd.2013.2213. doi: 10.1038/jp.2016.122. Epub 2016 Aug 4. doi: 10.1111/bjd.13265. Epub 2015 Jan 7. doi: 10.1002/mrc.4048. Epub 2014 Jan 27. doi: 10.1111/j.1742-7843.2011.00842.x. Epub 2012 Jan 16. doi: 10.1208/s12249-015-0441-7. Epub 2015 Oct 28. Erratum in: AAPS PharmSciTech. 2016 Dec;17 (6):1507. doi: 10.1016/j.jphotobiol.2014.05.024. Epub 2014 Jun 28. doi: 10.1007/s15010-015-0826-2. Epub 2015 Jul 28. doi: 10.1016/j.msec.2014.01.008. Epub 2014 Jan 10.

    合成参考文献


    摘要:Oguz H, Demirci M, Arslan N, Safak MA, Paksoy G. Necrotizing fasciitis of the head and neck: Report of two cases and literature review. Ear Nose Throat J. 2010 Feb;89(2):E7–10.
    参考文献:10.1016/j.anaerobe.2010.02.003
    摘要:Boente RF, Ferreira LQ, Falcão LS, Miranda KR, Guimarães PL, Santos-Filho J, Vieira JM, Barroso DE, Emond JP, Ferreira EO, Paula GR, Domingues RM. Detection of resistance genes and susceptibility patterns in Bacteroides and Parabacteroides strains. Anaerobe. 2010 Jun;16(3):190–4. doi: 10.1016/j.anaerobe.2010.02.003.
    参考文献:10.1128/aac.00561-11
    摘要:Pannu J, McCarthy A, Martin A, Hamouda T, Ciotti S, Ma L, Sutcliffe J, Baker JR. In vitro antibacterial activity of NB-003 against Propionibacterium acnes. Antimicrob Agents Chemother. 2011 Sep;55(9):4211–7.
    摘要:Roberts S, Heffernan H, Al Anbuky N, Pope C, Paviour S, Camp T, Swager T. Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009. N Z Med J. 2011 Apr 15;124(1332):45–51.
    参考文献:10.1136/bcr.03.2009.1639
    摘要:Lee H, Idrees Z, Kinsella F. Clostridium perfringensendophthalmitis following perforating eye injury. BMJ Case Reports. 2009;2009():bcr0320091639. doi: 10.1136/bcr.03.2009.1639.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知